Acadia Pharmaceutica (ACAD) Stock Price, Quote & News

Company Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndro...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 558 2871

Fax: 858 558 2872

Website: www.acadia.com

Address:

12830 El Camino Real, Suite 400, San Diego, United States

SBL71 Jul. 14 at 1:23 PM

$ACAD Q3. Let’s go

0 · Reply

Night_Owl_Biotech Jul. 12 at 9:22 PM

Updated revenue multiples on a peer group of commercial-stage non-oncology focused biopharmas with 1st FDA approvals between 2020 & 2023 (plus PTCT & ACAD) Analysts project ARDX $TARS & $MIRM to generate roughly the same revenues over the next 5 & 10 years yet MIRM trades at the highest multiple of the 3. This may be due to MIRM's low SG&A expenses versus the 2 offset by lower gross margins. This is not investment advice. We're merely sharing our analysis. TARS valuation is off ~$500MM after investing $75MM to acquire a, perhaps boring, bio with a compound in P3. Simple analytics suggest, by itself, TARS is oversold but of course we c/b wrong We include $ACAD & PTCT because their profiles appear identical yet ACAD trades at half their valuation. We should note PTCT's EV includes ~$2B from a royalty obligation. Some argue royalty sales/obligations should be excluded from valuation. This could be misleading so do your own diligence. $BBIO now trades @ the highest multiple after $IONS

0 · Reply

Night_Owl_Biotech Jul. 9 at 11:25 PM

This is an update to our $ACAD v $PTCT post from a few weeks ago. Both have gained 20-25% since 6/10/26 when the $XBI began its recent surge. Analysts project ACAD to slightly outsell PTCT over the next 5 & 10 years. Both generate the same gross margins yet ACAD's market cap & enterprise value are roughly half of PTCT. The objective of this post is to ID the disconnect between the 2. This is not to bash PTCT (which incidentally trades at lower multiples than peers with more recent approvals like $INSM & $ASND ). We'd genuinely appreciate a PTCT perspective. We added analyst EPS estimates & related multiples that identify the same disconnect in valuation. Genuine feedback would be sincerely appreciated. This is not investment advice.

2 · Reply

ReapN Jul. 8 at 2:57 PM

$SLS Still Living ! $CPXX $JAZZ $ACAD Quality of Life. $LLY

0 · Reply

raylin Jul. 7 at 9:08 PM

$ACAD Open the checkbook Mr. Big Pharma. We’re at the altar and ready to consummate…..🦵🏻🫦

1 · Reply

zeustony88 Jul. 7 at 5:00 PM

$ACAD Early August ADP readout?

0 · Reply

raylin Jul. 7 at 4:46 PM

$ACAD Hey Ms Adams and Baker Bros:

0 · Reply

zeustony88 Jul. 2 at 8:03 PM

$ACAD Not a bad week...Happy 4th!

0 · Reply

Quantumup Jul. 2 at 11:41 AM

Citizens reitd $TSHA Mkt OP-$11 $NGNE $ACAD AVXL Citizens said: Overall, we come away positive from the meeting for TSHA-102 and recommend the stock ahead of pivotal data and regulatory feedback in 1H27. At a high level, attendees were convinced by the early results, with an emphasis on improved communication and grasping, which have a very high impact on QoL. "How can we compare pivotal efficacy across programs?" remained unanswered. To our surprise, doctors at centers of excellence and patients did not mind Neurogene's (NGNE, NC) more-involved ICV delivery over TSHA's IT delivery. Some doctors worry about access, given trofinetide is getting more burdensome. However, the current high response rate will help gene therapies in this regard. An FDA representative (non-gene Tx) is not a proponent of responder analysis since it collapses rich information onto a lower dimension. However, she highlighted it is important in a heterogeneous disease and was appreciative of TSHA's work around validation.

0 · Reply

JuggernautRaider Jul. 1 at 7:43 AM

$TNXP $TLSA $CGTX $ACAD are all looking Good, @Night_Owl_Biotech 🏦 How come ACAD hasn’t been bought yet? Like AVXL and AXSM… the longer they stay independent, the worst their prognosis becomes 🤢 The new GHCA - Global Hc Academy Platform - is launching soon! Thanks to my man @Proposition_Joe , @Imno1 , and @AkBearHunter for inspiring my new business idea. We plan to change the game on biopharma and healthcare investment EDUCATION. More coming soon; working on the new website as I type 🤫

2 · Reply

Acadia Pharmaceuticals price target raised to $36 from $29 at RBC Capital

2026-07-06T13:10:55.000Z - 8 days ago

Acadia Pharmaceuticals appoints Carl Segerstorm as CPO

Jul 6, 2026, 9:04 AM EDT - 8 days ago

Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer

2026-06-30T11:55:20.000Z - 15 days ago

Acadia Pharmaceuticals price target raised to $30 from $29 at BofA

2026-06-29T12:55:19.000Z - 15 days ago

Acadia Pharmaceuticals price target raised to $37 from $32 at Deutsche Bank

2026-06-29T11:06:28.000Z - 16 days ago

Acadia Pharmaceuticals price target raised to $36 from $32 at Canaccord

2026-06-29T00:30:07.000Z - 16 days ago

Citi adds ‘upside 90-day catalyst watch’ on Acadia Pharmaceuticals

2026-06-29T00:25:05.000Z - 16 days ago

Acadia Pharmaceuticals price target raised to $35 from $32 at Citi

2026-06-26T16:06:26.000Z - 18 days ago

Acadia Pharmaceuticals rises 13.4%

2026-06-26T15:16:12.000Z - 18 days ago

Acadia Pharmaceuticals Stock (ACAD) Jumps on a Positive CHMP Review

2026-06-26T14:00:13.000Z - 18 days ago

Acadia Pharmaceuticals rises 9.9%

2026-06-26T10:55:09.000Z - 19 days ago

Acadia Pharmaceuticals: Daybu recommended for approval in EU by CHMP

Jun 26, 2026, 6:49 AM EDT - 19 days ago

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

May 19, 2026, 9:00 AM EDT - 2 months ago

ACADIA Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 12, 2026, 7:20 PM EDT - 2 months ago

ACADIA Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026

2026-05-08T11:24:17.000Z - 2 months ago

Acadia Pharmaceuticals price target lowered to $32 from $33 at Citi

2026-05-07T01:48:00.000Z - 2 months ago

Acadia Pharmaceuticals reports Q1 EPS 2c, consensus 8c

2026-05-07T01:47:22.000Z - 2 months ago

Acadia Pharmaceuticals backs FY26 revenue view $1.22B-$1.28B, consensus $1.25B

May 6, 2026, 4:30 PM EDT - 2 months ago

ACADIA Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

ACADIA Pharmaceuticals Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

ACADIA Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

ACADIA Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 4:05 PM EDT - 2 months ago

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

Apr 30, 2026, 4:05 PM EDT - 2 months ago

Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D.

Apr 28, 2026, 4:05 PM EDT - 2 months ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Apr 24, 2026, 8:00 AM EDT - 2 months ago

ACADIA Pharmaceuticals Proxy statement: Proxy filing

Apr 17, 2026, 9:05 AM EDT - 3 months ago

Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

Apr 15, 2026, 4:05 PM EDT - 3 months ago

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

2026-04-07T15:14:31.000Z - 3 months ago

Acadia Pharmaceuticals price target lowered to $29 from $30 at RBC Capital

2026-04-07T13:44:52.000Z - 3 months ago

Acadia Pharmaceuticals announces Daybue Stix available in U.S.

Apr 7, 2026, 9:05 AM EDT - 3 months ago

Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

2026-03-25T10:20:13.000Z - 4 months ago

Acadia Pharmaceuticals upgraded to Buy at BofA following 25% pullback

Mar 17, 2026, 8:00 AM EDT - 4 months ago

ACADIA Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum

Mar 12, 2026, 4:05 PM EDT - 4 months ago

Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

Mar 11, 2026, 1:05 PM EDT - 4 months ago

ACADIA Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 3, 2026, 4:05 PM EST - 4 months ago

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

Mar 2, 2026, 4:05 PM EST - 4 months ago